Black Rock Inc. Scynexis Inc Transaction History

Black Rock Inc.

$4.23 Trillion
Q1 2024

A detailed history of Black Rock Inc. transactions in Scynexis Inc stock. As of the latest transaction made, Black Rock Inc. holds 341,733 shares of SCYX stock, worth $645,875. This represents 0.0% of its overall portfolio holdings.

Number of Shares

341,733

Previous 434,078 21.27%

Holding current value

$645,875

Previous $967,000 48.09%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$1.39 - $2.21 $128,359 - $204,082	-92,345 Reduced 21.27%	341,733 $502,000
Q4 2023 Feb 13, 2024	BUY	$1.56 - $2.24 $4,945 - $7,100	3,170 Added 0.74%	434,078 $967,000
Q3 2023 Nov 13, 2023	BUY	$1.93 - $3.64 $3,348 - $6,315	1,735 Added 0.4%	430,908 $982,000
Q2 2023 Aug 11, 2023	BUY	$2.38 - $3.67 $117,286 - $180,857	49,280 Added 12.97%	429,173 $1.27 Million
Q1 2023 May 12, 2023	SELL	$1.15 - $3.0 $45,548 - $118,821	-39,607 Reduced 9.44%	379,893 $1.14 Million

Q4 2022 Feb 13, 2023	BUY	$1.46 - $2.49 $2,560 - $4,367	1,754 Added 0.42%	419,500 $654,000
Q3 2022 Nov 14, 2022	SELL	$1.83 - $2.93 $411 - $659	-225 Reduced 0.05%	417,746 $1 Million
Q2 2022 Aug 12, 2022	BUY	$1.77 - $3.87 $76,163 - $166,526	43,030 Added 11.48%	417,971 $778,000
Q1 2022 May 12, 2022	SELL	$3.56 - $6.66 $1,085 - $2,031	-305 Reduced 0.08%	374,941 $1.47 Million
Q4 2021 Feb 10, 2022	BUY	$4.94 - $7.69 $250,868 - $390,521	50,783 Added 15.65%	375,246 $2.29 Million
Q3 2021 Nov 09, 2021	SELL	$5.3 - $7.89 $21,173 - $31,520	-3,995 Reduced 1.22%	324,463 $1.72 Million
Q2 2021 Aug 11, 2021	BUY	$6.5 - $9.97 $2.13 Million - $3.27 Million	328,458 New	328,458 $2.42 Million

Others Institutions Holding SCYX

# of Institutions

Shares Held

15.4M

Call Options Held

Put Options Held

12.9K

View Full List

About SCYNEXIS INC

Ticker SCYX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 32,651,800
Market Cap $61.7M
Description
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of vario...

More about SCYX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account